Combinostics Oy

Combinostics Oy is a Finnish company focused on AI-driven solutions for the early detection and management of neurological disorders, enhancing diagnostic accuracy through automated imaging technologies. Founded in 2014 in Tampere, Finland, Combinostics Oy specializes in providing advanced diagnostic tools for healthcare professionals. The company's founders include Juha Koikkalainen, Jussi Mattila, and Markus Niiranen, while Lennart Thurfjell serves as CEO. Combinostics has completed 6 deals and recently raised EUR 4.

30 mn through a Trade Sale from investor SyntheticMR AB, totaling EUR 4. 30 mn raised since inception. Combinostics specializes in advanced AI-driven solutions designed to enhance the early detection, diagnosis, and management of major neurological disorders. The company's flagship products, cNeuro® cMRI™ and cNeuro cDSI™, leverage a cloud-based platform to provide fully automated brain MRI quantification and integrate imaging data with comprehensive patient information.

This innovative approach allows neurologists and radiologists to make informed diagnoses by assessing disease progression and making testing decisions based on a blend of imaging results and clinical data. These products are primarily utilized by healthcare professionals across Europe and the United States, serving hospitals, memory clinics, and other medical facilities that focus on neurological health. Their technology aligns with the needs of a diverse client base, including neurologists, radiologists, and healthcare institutions, who require precise and timely diagnostic tools to improve patient outcomes. Combinostics operates on a subscription-based revenue model, providing access to its cNeuro platform and associated applications to healthcare organizations and professionals.

For the most recent year, 2023, the company reported a revenue of EUR 559,332. 30 and an EBITDA of EUR -1,717,907. 90. Clients engage in partnerships where they subscribe to the services, allowing for continuous access to the AI tools necessary for neurological assessment and diagnosis.

The revenue structure includes various pricing plans tailored to the specific needs of client facilities, facilitating the integration of cNeuro® services into their diagnostic workflows. Combinostics Oy plans to leverage recent funding to enhance its product offerings and expand into new markets. The company is currently working on developing new features for its existing products and aims to enter additional European markets by the end of 2024. The recent investment from M&M Growth Partners will support these initiatives, strengthening their capabilities in AI-driven diagnostics and broadening their reach within the healthcare sector.